TAIWAN · TWSE / TPEx
Lotus Pharm
美時 · 1795 · TWSE (main board) · Biotech and medical
Share price, 2026-10-19NT$176.001 month -1.4% · 1 year -32.1%
Directors and supervisors hold100,499,52837.2% of shares issued
Of which pledged0.0%0
Major shareholders (10%+) hold82,754,33730.6% of shares issued
Revenue, 2026-09+128.0%year on year
Share price, last 12 months
Daily closes adjusted for cash and stock dividends, against the TAIEX index rebased to the same start. Prices from Yahoo Finance.
Directors, officers and major shareholders
Holdings reported for 2026-09. At election = shares held when the director was elected. Related parties = holdings of the person's spouse, minor children and nominees. One person with two roles is listed once.
| Person | Role | At election | Now | Of the company | Pledged | Related parties |
|---|---|---|---|---|---|---|
| Vilhelm Robert Wessman | Chairman | — | 0 | — | — | — |
| Arni Hardarson | Director | — | 0 | — | — | — |
| Oranee Tangphao Daniels | Director | — | 0 | — | — | — |
| Yves Hermes | Director | — | 0 | — | — | — |
| 美商摩根大通銀行台北分行受託保管ＩＮＮＯＢＩＣ有限責任控股公司投資專戶 | Director | 17,517,348 | 17,745,191 | 6.57% | — | — |
| Nat Ativitavas | Director (corporate representative) | — | 0 | — | — | — |
| Orakul Suebsiri | Director (corporate representative) | — | 0 | — | — | — |
| Krisana Winitthumkul | Director (corporate representative) | — | 0 | — | — | — |
| 香港商INNOBIC ASIA INVESTMENT HOLDING LIMITED | Director · Major shareholder (10%+) | 82,446,796 | 82,754,337 | 30.65% | — | — |
| Petar Antonov Vazharov | Director (corporate representative) · President | — | 1,513,006 | 0.56% | — | — |
| 王傳芬 | Independent director | — | 0 | — | — | — |
| Karl Alexius Tiger Karlsson | Independent director | — | 0 | — | — | — |
| 楊郁民 | Independent director | — | 0 | — | — | — |
| 謝明君(Gwen Hsieh) | Vice president | — | 57,403 | 0.02% | — | — |
| 田依菱 | Vice president · Chief financial officer · Chief accountant | — | 43,559 | 0.02% | — | — |
| 沈燁(Bjartur Shen) | Vice president | — | 240,951 | 0.09% | — | — |
| ＥＤＩＮ ＢＵＬＪＵＢＡＳＩＣ | Vice president | — | 151,951 | 0.06% | — | — |
| Vamsi Kiran Kosaraju | Vice president | — | 91,170 | 0.03% | — | — |
| 劉秀麗(Lau Siew Lay) | Vice president | — | 151,951 | 0.06% | — | — |
| Torrejon Nieto Javier | Vice president | — | 202,601 | 0.08% | — | — |
| Venkata Rama Prasad Yarasani | Vice president | — | 40,000 | 0.01% | — | — |
| Mayank Mathuriya | Vice president | — | 0 | — | — | — |
| Lumtunie Tunie Zaku | Vice president | — | 0 | — | — | — |
| 廖苑珊 | Other | — | 8,104 | 0.00% | — | — |
Exchange announcements
| Date | |
|---|---|
| 2026-10-16 | 代子公司Alvogen Pharma US Inc. 依「公開發行公司資金貸與及背書保證處理準則」 第二十二條第一項第二款規定公告 |
| 2026-10-16 | 代子公司Alvogen Inc. 依「公開發行公司資金貸與及背書保證處理準則」 第二十二條第一項第二款規定公告 |
| 2026-10-16 | 代子公司Alvogen Group Inc. 依「公開發行公司資金貸與及背書保證處理準則」 第二十二條第一項第二款規定公告 |
| 2026-10-16 | 代子公司Lotus Pharma Bulgaria EOOD 依「公開發行公司資金貸與及背書保證處理準則」 第二十二條第一項第二款規定公告 |